Cutis Laxa with Congenital Disorder of Glycosylation (CDG)

Cutis laxa with congenital disorder of glycosylation (CDG) is a rare inherited condition where a baby is born with loose, saggy skin (cutis laxa) and multisystem problems caused by a genetic error in adding sugar chains to proteins (glycosylation). One classic form is due to ATP6V0A2 gene changes (also called autosomal recessive cutis laxa type 2, ARCL2). In this condition, both N-linked and O-linked glycosylation can be abnormal, which helps explain skin laxity plus brain, growth, connective-tissue, and organ findings. There is no single cure; care focuses on early diagnosis, surveillance, supportive therapies, and targeted treatments for specific complications (for example, nutrition, seizures, reflux, infections, coagulation, and hernias). NCBI+3NCBI+3Nature+3

Cutis laxa means the skin is loose, wrinkled, and hangs in folds. In some children this happens because of a congenital disorder of glycosylation (CDG). Glycosylation is a basic “sugar tagging” process that helps proteins fold, travel, and work normally—especially the proteins that make and organize elastic fibers in skin and other tissues. When glycosylation is faulty—most classically from defects in the vacuolar proton pump (V-ATPase) or Golgi trafficking—proteins are processed abnormally. This leads to poor elastic-fiber assembly, loose skin, and multi-system problems such as developmental delay, brain MRI changes, bone and joint issues, and sometimes heart-lung involvement. A well-studied example is ATP6V0A2-related cutis laxa, which shows a combined N- and O-glycosylation defect on laboratory testing. PMC+3NCBI+3Nature+3

Other names

• ATP6V0A2-related cutis laxa (formerly called autosomal recessive cutis laxa type 2A, ARCL2A) and wrinkly skin syndrome (WSS)—historical labels for the same clinical spectrum linked to ATP6V0A2. NCBI+2PMC+2

• V-ATPase-related CDG with cutis laxa—an umbrella term that includes ATP6V0A2-CDG and rare ATP6V1E1-CDG and ATP6V1A-CDG forms with similar skin findings plus systemic features. PubMed+2ScienceDirect+2

• Metabolic cutis laxa syndromes—a group label for cutis laxa caused by inborn errors of metabolism, especially CDG. PMC+1

Types

1. ATP6V0A2-CDG (ARCL2A / WSS spectrum). This is the prototypical, best-described form. Babies have hypotonia, over-folded skin, enlarged fontanelles, and later developmental delay and brain MRI changes; labs show combined N- and O-glycosylation defects. NCBI+1

2. ATP6V1E1-CDG (V-ATPase E1 subunit). Biallelic variants in ATP6V1E1 cause cutis laxa with variable severity, characteristic facial features, and cardiopulmonary findings. PubMed+1

3. ATP6V1A-CDG (ARCL type IID). Biallelic ATP6V1A variants produce a similar “metabolic cutis laxa” picture; several families have been reported. ScienceDirect+1

4. COG-complex CDG with wrinkly skin. Early reports linked COG7-CDG (a Golgi trafficking defect) to inelastic, wrinkly skin—establishing one of the first CDG–cutis laxa connections. PMC+1

5. SLC10A7-CDG (skeletal dysplasia ± cutis laxa features). Some patients show joint laxity, bone changes, and enamel defects; the core mechanism involves disturbed O-glycosylation and secretory pathway calcium balance, which can secondarily affect extracellular matrix. PubMed+1

Note: There are other cutis laxa genes (e.g., PYCR1, ALDH18A1, LTBP4, EFEMP2) that are not CDG; they are listed here only to highlight that the “cutis laxa” umbrella contains multiple subgroups, and the CDG-associated subgroup is the topic of this article. ScienceDirect

 Causes

1. Pathogenic variants in ATP6V0A2. This disrupts the V-ATPase a2 subunit, altering Golgi acidity, protein processing, and elastic-fiber assembly, leading to loose skin and multi-system signs. NCBI+1

2. Pathogenic variants in ATP6V1E1. Damage to the E1 subunit of V-ATPase disrupts intracellular acidification, causing a metabolic cutis laxa with facial, cardiac, and pulmonary features. PubMed+1

3. Pathogenic variants in ATP6V1A. Loss of the A subunit affects V-ATPase energy-coupling and glycosylation, producing ARCL with systemic involvement. ScienceDirect+1

4. COG7 (Golgi trafficking) defects. Early “wrinkly skin” cases showed that COG-complex failure can cause CDG with cutis laxa by mis-sorting glycoproteins. PMC+1

5. Broader Golgi/trafficking pathway defects. Abnormal Golgi pH or transport (e.g., other COG subunits) can secondarily impair glycosylation and elastogenesis. PMC

6. Disturbed O-glycosylation via SLC10A7. This transporter’s loss alters O-glycan maturation and Ca²⁺ handling in the secretory pathway, weakening connective tissues. PubMed+1

7. Combined N- and O-glycosylation defects. ATP6V0A2-CDG typically shows both N- and O-glycan abnormalities, explaining widespread connective tissue changes. Nature

8. Missense variants that change key amino acids. These can subtly deform V-ATPase subunits, disturbing proton pumping and glycoprotein processing. ScienceDirect

9. Truncating variants (nonsense/frameshift). Shortened proteins often lose function completely, producing more severe phenotypes. NCBI

10. Splice-site variants. Incorrect splicing yields faulty transcripts and reduced functional protein. NCBI

11. Compound heterozygosity. Two different harmful variants (one on each allele) commonly cause autosomal recessive forms. NCBI

12. Founder effects in small populations. Certain variants may be more frequent in specific groups due to ancestry and limited outbreeding. ScienceDirect

13. Modifier genes. Background genetic differences can shift severity by altering matrix assembly or glycan pathways. (Inference grounded in CDG variability.) PMC

14. Golgi acidification failure. Without proper acidity, glycosylation enzymes mis-function—central to V-ATPase-linked CDG. PubMed

15. Defective protein trafficking. Misdelivery of enzymes and cargo in the secretory pathway impairs elastic-fiber components. PMC

16. Abnormal extracellular matrix (ECM) assembly. Faulty glycosylation derails elastin/fibrillin handling, weakening skin’s recoil. PubMed

17. Prenatal onset of connective-tissue weakness. Signs may begin before birth, fitting with early developmental roles of glycosylation. NCBI

18. Autosomal recessive inheritance. Both copies of the gene must carry a pathogenic variant to express disease. NCBI

19. Rare de novo events. Occasionally, a new mutation can cause the condition even without family history. (Supported across CDG literature.) PMC

20. Global CDG pathway disruption. Beyond single genes, any strong hit to glycosylation logic can drive the phenotype toward cutis laxa in some patients. PMC

Symptoms and signs

1. Loose, hanging, wrinkled skin (cutis laxa). The skin looks prematurely aged and does not “snap back” because elastic fibers are poorly assembled. NCBI+1

2. Enlarged soft spots (fontanelles) and delayed closure. Abnormal connective tissue around skull sutures can slow closing. NCBI

3. Hypotonia (low muscle tone). Babies feel “floppy,” reflecting multi-system involvement and sometimes central nervous system changes. NCBI

4. Developmental delay. Milestones may be late; some children have intellectual disability of variable degree. NCBI

5. Distinctive facial features. A triangular or progeroid face and coarse hair can appear over time. NCBI+1

6. Joint laxity and dislocations. Loose ligaments can allow hips or other joints to dislocate. PMC

7. Hernias (umbilical/inguinal). Weak connective tissue can bulge at natural openings. NCBI

8. Scoliosis or other spine curves. Lax connective tissue in ligaments contributes to deformity. PubMed

9. Feeding difficulties and poor growth. Low tone and systemic illness can cause failure to thrive. NCBI

10. Seizures (in some children). Neurologic involvement can include epilepsy. NCBI

11. Abnormal brain MRI. White matter changes and other structural findings are common in ATP6V0A2-related disease. NCBI

12. Eye problems. Strabismus or refractive errors may occur; rare cataracts are reported in V-ATPase forms. PMC

13. Hearing issues (some cases). Conductive or sensorineural loss can accompany CDG. PMC

14. Heart or lung involvement (especially V-ATPase forms). Some families show cardiomyopathy or pulmonary disease. ScienceDirect

15. Bone and teeth differences (more with SLC10A7-CDG). Skeletal dysplasia, large-joint issues, and enamel defects can be part of the picture. PubMed

Diagnostic tests

A) Physical examination

1. Whole-body skin inspection. Doctors look for loose, redundant skin that stays wrinkled after gentle stretching, which points toward cutis laxa. ScienceDirect

2. Craniofacial exam. Triangular/progeroid facial shape, coarse hair, and large fontanelles help distinguish this subtype. NCBI

3. Hernia check. Umbilical or inguinal hernias are common clues to connective tissue weakness. NCBI

4. Growth and nutrition assessment. Weight, length/height, and head size trends reveal failure to thrive or disproportion. NCBI

5. Spine and joint exam. Laxity, scoliosis, and hip stability are checked carefully in infants and children. PubMed

B) Manual/bedside tests

6. Skin recoil (“snap back”) test. Gently pulling the skin and watching the slow return supports cutis laxa (distinct from hyperextensible EDS). ScienceDirect

7. Beighton joint laxity scoring. Simple maneuvers quantify generalized laxity that often accompanies the skin findings. ScienceDirect

8. Developmental screening (e.g., Denver). Bedside milestone checks flag delays needing fuller evaluation. NCBI

9. Vision and hearing screens. Office-based tests can pick up strabismus or hearing loss for formal referral. PMC

10. Neurologic bedside exam. Tone, reflexes, and coordination help map the degree of central involvement. NCBI

C) Laboratory & pathological tests

11. Serum transferrin isoelectric focusing (TIEF) or sialotransferrin HPLC. This is the front-line test for N-glycosylation defects; ATP6V0A2-CDG shows a characteristic combined pattern. Nature+1

12. Apolipoprotein C-III isofocusing. Screens for O-glycosylation abnormalities that frequently accompany V-ATPase CDG. iembase.org

13. Glycomics by mass spectrometry. Defines abnormal glycan structures to confirm and subtype CDG. PMC

14. Liver enzymes and coagulation factors. Abnormalities are common across CDG and support a systemic glycosylation disorder. PMC

15. Molecular genetic testing (targeted gene panel or exome). Confirms biallelic pathogenic variants in ATP6V0A2, ATP6V1E1, ATP6V1A, or related genes. NCBI+1

16. Skin biopsy (histology). Can show fragmented, reduced elastic fibers—supportive when genetic testing is pending. ScienceDirect

17. Fibroblast studies (specialized). Cellular assays may demonstrate trafficking or glycosylation defects in research/tertiary settings. PMC

D) Electrodiagnostic tests

18. EEG. Used if seizures or concerning spells occur; patterns may reflect underlying brain dysfunction. NCBI

19. Nerve conduction studies/EMG. Considered when weakness or neuropathy is suspected. PMC

20. ECG/telemetry (cardiac electrical testing). Screens for rhythm problems in patients with cardiomyopathy risk in V-ATPase forms. ScienceDirect

E) Imaging tests

• Brain MRI. Often abnormal in ATP6V0A2-related disease (e.g., white-matter or structural changes) and helps explain neurologic symptoms. NCBI

• Echocardiogram and chest imaging. Evaluates structural heart disease or pulmonary involvement reported in some V-ATPase defects. ScienceDirect

• Skeletal survey / targeted X-rays. Looks for scoliosis, hip dislocation, or other skeletal differences. PubMed

• Abdominal ultrasound. Checks for organ enlargement or hernia complications in multi-system CDG. PMC

• Dental imaging (selected). In SLC10A7-CDG with enamel defects, dental films help plan care. PubMed

Non-pharmacological treatments (therapies & others)

Important: These are supportive/rehabilitative measures tailored to each child. Multidisciplinary care is essential. NCBI+1

1. Genetic counseling & care coordination — explain inheritance, recurrence risk, and connect the family to specialists; update the plan as new evidence emerges in CDG. NCBI

2. Physiotherapy (motor tone, posture, balance) — guided stretching/strengthening to reduce hypotonia impact and improve milestones; home programs help maintain gains. NCBI

3. Occupational therapy — hand skills, feeding positioning, and adaptive tools for daily living; gradual, task-oriented practice improves participation. NCBI

4. Speech-language therapy — supports oral-motor skills, communication, and safe swallowing; early intervention improves feeding and language outcomes. NCBI

5. Feeding plans & reflux positioning — smaller, more frequent feeds; upright positioning; thickened feeds as advised; protects nutrition and reduces aspiration risk. NCBI

6. Registered-dietitian care — optimize calories/protein; monitor fat-soluble vitamins if cholestasis; tailor carbohydrates for hypoglycemia-prone subtypes (e.g., PGM1-CDG). PMC

7. Skin care routines — gentle cleansers, emollients, sun protection; treat intertrigo in skin folds; aim to reduce irritation in lax skin. ERN ITHACA

8. Hernia belts/watchful waiting — temporary support while planning surgery when indicated; urgent referral for incarceration signs. ERN ITHACA

9. Developmental/early-intervention services — structured, play-based learning; family coaching for home carryover. NCBI

10. Vision services — refraction correction/occlusion therapy for strabismus to support development. NCBI

11. Seizure safety education — first-aid steps, trigger logs, and care plans for school/daycare. NCBI

12. Infection-prevention practices — hand hygiene, vaccination per schedule, RSV season strategies if high-risk. Frontiers

13. Liver-friendly measures — avoid unnecessary hepatotoxic meds; monitor labs; nutrition to support growth and fat-soluble vitamin status. NCBI

14. Orthotics & adaptive seating — help trunk control and prevent contractures; customize per therapist assessment. NCBI

15. Respiratory physiotherapy (as needed) — airway clearance if recurrent infections. NCBI

16. Psychosocial support — connect with CDG and cutis laxa communities; address caregiver stress. BioMed Central

17. Educational supports/IEPs — tailored learning plans and therapies in school. NCBI

18. Transition planning (adolescence→adult) — continuity of specialty follow-up and self-management skills. NCBI

19. Emergency care plans — seizure rescue steps, bleeding risk, and surgical history for teams. PMC

20. Clinical trial/registry awareness — learn about evolving CDG research and natural-history studies. PMC

---

Drug treatments

Key note: No medicine is FDA-approved for “cutis laxa with CDG.” The drugs below are used to treat complications (seizures, reflux, infections, cholestasis, pancreatic insufficiency, coagulation). Dosing must be individualized by specialists. I cite accessdata.fda.gov labels for each drug’s official indications/safety; use in CDG is typically off-label.

1. Levetiracetam for seizures — broad-spectrum antiseizure drug; oral solution/tablets; titrate to effect; common adverse events include somnolence and irritability. Class: anticonvulsant. Dose/Timing: per label by age/weight; divided doses. Purpose/Mechanism: reduces neuronal hyperexcitability (SV2A binding). Key safety: mood/behavior monitoring. FDA Access Data+2FDA Access Data+2

2. Omeprazole for GERD/reflux — improves esophagitis and symptoms that worsen feeding. Class: proton-pump inhibitor. Dose/Time: once daily before meals (pediatric dosing per prescriber). Mechanism: blocks gastric H+/K+-ATPase. Safety: headache, abdominal pain; long-term risks discussed in label. FDA Access Data+2FDA Access Data+2

3. Baclofen for spasticity/hypertonia episodes (some children alternate tone states) — Class: GABA-B agonist. Dose: start low, titrate; Timing: divided daily. Side effects: sedation, hypotonia. Mechanism: reduces spinal reflex excitability. FDA Access Data+2FDA Access Data+2

4. Pancrelipase (CREON) when exocrine pancreatic insufficiency is documented (not universal in CDG) — improves fat absorption, growth, and steatorrhea. Class: pancreatic enzymes. Dose: by lipase units with meals/snacks. Safety: fibrosing colonopathy (high dose), oral irritation if chewed. FDA Access Data+2FDA Access Data+2

5. Ursodiol (URSO/Actigall) for cholestasis or PBC-like cholestatic patterns in select cases (specialist-directed) — enhances bile flow. Dose: ~13–15 mg/kg/day in divided doses (adult label; pediatric use is specialist/off-label). Safety: GI effects; drug interactions. FDA Access Data+2FDA Access Data+2

6. Phytonadione (vitamin K1) for coagulopathy with low vitamin-K–dependent factors — corrects hypoprothrombinemia. Dose/Route: per label and INR monitoring. Safety: rare hypersensitivity with IV; use minimal effective dose. FDA Access Data+2FDA Access Data+2

7. IVIG (immune globulin) for selected patients with recurrent infections/hypogammaglobulinemia — Purpose: reduce serious infections. Class: immune globulin. Safety: headache, thrombosis risk; infusion protocols apply. (Example product: Gamunex-C.) FDA Access Data

8. Palivizumab (seasonal) for RSV prophylaxis in high-risk infants (prematurity, CLD, CHD)—decision individualized. Dose: monthly IM during RSV season. Safety: fever, injection site reactions. (Note: newer long-acting options exist; avoid co-administration with nirsevimab in same season.) FDA Access Data+1

9. Acid suppression alternatives (if omeprazole not tolerated): prescribers may use other PPIs/H2 blockers per label; risks/benefits reviewed by GI. FDA Access Data

10. Antiemetics short-term for severe vomiting under specialist care; monitor QT and interactions per label. UpToDate

11. Anticonvulsant alternatives (e.g., valproate, topiramate) chosen by neurology according to seizure type and comorbidities. Label safety dictates monitoring (liver, ammonia, cognitive effects). UpToDate

12. Antibiotics for documented infections per culture; stewardship principles apply. UpToDate

13. Bronchodilators/inhaled therapies if reactive airway disease is diagnosed; use label-based dosing and monitoring. UpToDate

14. Vitamin D and fat-soluble vitamin formulations when cholestasis or malabsorption is present; dosing per nutrition/hepatology guidance and product labels. FDA Access Data

15. Laxatives/osmotics for constipation associated with hypotonia or diet; label-guided pediatric dosing and hydration. UpToDate

16. Proton-pump inhibitor weaning strategies (when appropriate) to limit long-term adverse effects, done medically supervised. FDA Access Data

17. Analgesics/antipyretics (acetaminophen/ibuprofen) for pain/fever per pediatric labels; watch hepatic function if liver involvement. UpToDate

18. Topical barrier creams/antifungals for intertrigo; use per label to protect lax skin folds. ERN ITHACA

19. Iron supplementation when deficiency is proven; dosing and monitoring per pediatric guidelines/labels (avoid excess). UpToDate

20. Emergency seizure rescue meds (e.g., intranasal midazolam) as prescribed; families trained in use; follow label warnings. UpToDate

---

Dietary molecular supplements

Supplements do not cure CDG or cutis laxa. Use only with clinician guidance to avoid interactions or excess. Evidence below reflects general physiology (collagen, immunity, anti-inflammation), not disease-specific reversal.

1. Vitamin C — key for collagen formation and antioxidant defense; typical RDA-based dosing; excess may cause GI upset or kidney stones in predisposed people. Office of Dietary Supplements+2Office of Dietary Supplements+2

2. Zinc — supports immune function, wound healing, and protein/DNA synthesis; avoid high-dose chronic use (copper deficiency risk). Office of Dietary Supplements+1

3. Omega-3 fatty acids (EPA/DHA) — cell-membrane support and anti-inflammatory effects; safe dose ranges depend on age and indication. Office of Dietary Supplements

4. Vitamin D — bone/immune support; dose to serum targets under supervision. FDA Access Data

5. Vitamin A (careful dosing) — epithelial integrity; avoid toxicity; monitor levels. FDA Access Data

6. Vitamin E — antioxidant; may be considered in fat-malabsorption with dietitian oversight. FDA Access Data

7. B-complex (including B1, B2, B6, niacin) — energy metabolism; parenteral nutrition formulas highlight interactions and stability. FDA Access Data

8. Selenium — antioxidant enzyme cofactor; avoid excess. Office of Dietary Supplements

9. Probiotics (strain-specific) — may help stool regulation; choose pediatric-studied strains. Office of Dietary Supplements

10. Calcium (diet first) — bone health; supplement only if intake is low or labs indicate need. Office of Dietary Supplements

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell or “regenerative” drugs for cutis laxa/CDG. The FDA warns that stem-cell/exosome products are not approved for most conditions; approved stem-cell products are umbilical cord blood–derived hematopoietic progenitor cells for certain blood disorders—not for CDG or cutis laxa. Be cautious of clinics offering unapproved therapies. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

Safer clinician-directed options that support immunity or tissue health:

1. Immune globulin (IVIG/SCIG) for select patients with documented antibody deficiency and recurrent infections (specialist decision; product labels apply). FDA Access Data

2. Palivizumab during RSV season for high-risk infants per label (prevention, not booster). FDA Access Data

3. Routine vaccines per schedule (not “drugs,” but core to immune protection). Frontiers

4. Nutritional repletion (vitamins/minerals above) to correct deficiencies that impair tissue repair/immune responses. Office of Dietary Supplements+1

5. Good sleep/nutrition/physiotherapy to support growth and resilience (behavioral “regeneration,” not a drug). NCBI

6. Avoid unapproved stem-cell clinics; discuss any “regenerative” claims with your specialist and review FDA resources together. U.S. Food and Drug Administration

---

Surgeries

1. Inguinal/umbilical hernia repair — fix symptomatic or complicated hernias; prevents incarceration/strangulation. ERN ITHACA

2. Abdominal wall/panniculectomy/dermolipectomy (select older patients) — improves hygiene/comfort where redundant skin impairs care; done after growth and with realistic goals. ERN ITHACA

3. Strabismus surgery — improves ocular alignment for vision development, if indicated by ophthalmology. NCBI

4. Gastrostomy (G-tube) — for severe feeding failure to ensure safe nutrition and growth. NCBI

5. Specialized vascular or airway procedures — only if imaging and symptoms demand it; individualized risk-benefit in connective-tissue laxity. ERN ITHACA

---

Preventions

Hygiene and vaccination; reflux-minimizing feeding routines; safe sleep/positioning; skin fold care to prevent rashes; early hernia monitoring; seizure safety plans; infection triggers avoidance during viral surges; medication review to avoid hepatotoxicity; regular dental/vision checks; and scheduled multidisciplinary follow-ups (neuro, genetics, GI/hepatology, nutrition, PT/OT/SLP). NCBI+1

---

When to see doctors (red flags)

Poor feeding, vomiting blood/bile, dehydration, failure to gain weight, persistent fever, repeated chest infections, seizure or unresponsive episodes, new bleeding/bruising, severe constipation or abdominal swelling, painful or non-reducible hernia, breathing difficulty, or any rapid change in tone or consciousness—seek urgent care and contact your specialty team. NCBI+1

---

What to eat & what to avoid

Eat more: balanced calories with protein at each meal; fruits/vegetables; sources of omega-3s (fish where appropriate); dairy or fortified alternatives; hydration; and dietitian-guided formulas when needed for growth or fat-soluble vitamin delivery. Avoid/limit: very acidic/irritating foods if reflux is severe; choking-risk textures if oral-motor issues; high-dose unproven supplements; and excessive fast foods that displace nutrient-dense options. Always individualize via a pediatric dietitian. NCBI+1

---

FAQs

1. Is there a cure? No; treatment focuses on early diagnosis, surveillance, rehab, and targeted therapies for complications. NCBI

2. Will skin laxity improve? Skin often remains lax; function and comfort can improve with skin care and, rarely, surgery. ERN ITHACA

3. Are there nutrition “fixes”? Only a few CDGs (not ATP6V0A2) respond to specific sugars (e.g., mannose for MPI-CDG, galactose for PGM1-CDG)—this is subtype-specific. PubMed+2Frontiers+2

4. Why test transferrin glycoforms? It screens for N-glycosylation defects and guides genetic testing. PMC

5. Do seizures happen in all patients? No, but they occur in some CDGs; neurology tailors antiseizure therapy. NCBI

6. Is reflux common? Yes; reflux can worsen feeding; combine positioning, feeding strategies, and medications when needed. FDA Access Data

7. What about immunity? Some CDG patients get frequent infections; immune workup and, rarely, IVIG are considered. FDA Access Data

8. Are stem-cell treatments available? Not for CDG or cutis laxa; beware unapproved clinics. U.S. Food and Drug Administration

9. How often should we check the liver? As advised by your team; periodic labs/ultrasound if cholestasis risk. NCBI

10. Could there be heart issues? Some CDGs have cardiac involvement; echocardiogram if symptoms or subtype suggest it. NCBI

11. Are hernias dangerous? Many are manageable but can incarcerate; surgical timing is individualized. ERN ITHACA

12. Who coordinates care? Genetics often coordinates with neurology, GI/hepatology, PT/OT/SLP, ophthalmology, and nutrition. NCBI

13. Will my next child be affected? Risk is 25% for autosomal recessive forms; genetic counseling helps with planning. NCBI

14. Are there guidelines? Yes—recent consensus documents and state-of-the-art reviews guide diagnosis/management. PMC+1

15. Where can we read more? GeneReviews entries for ATP6V0A2-related cutis laxa and PMM2-CDG provide clinician-level detail. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 06, 2025.